Sep 28 close
AbCellera Biologics closed at $13.92 on 28 September 2026, +9.6% on the day. The price sits above both the 50-day ($9.85) and 200-day ($5.77) moving averages, inside a 52-week range of $2.75 to $14.23. The GekkoIndex reads 43.5, in the Distribution zone, down 3.4 points over five sessions. Gekko Fair Value is $12.58, so the price is 10.7% above it.
The next earnings report is due on 5 November 2026, 37 days away (after close). Over the last 8 reports the company beat the earnings estimate 5 times, with an average move of 6.3% across the report. Smart-money activity over the last 90 days includes 4 open-market insider purchases. Over the last 30 days there was 1 unusual options signal. Seasonally, the next 20 trading days from this point averaged -0.8% over the last 5 years, rising in 3 of them.
8 firms rate the stock: 7 buy, 1 hold and 0 sell, with a consensus target of $16.67. A typical daily move is about 5.5%, and a typical 20-day move about 12.2%. On the swing-trade checklist, 3 items read supportive and 2 read as a headwind (gekkoindex, fair value).
Generated Sep 29, 2026 from the data above.
AbCellera Biologics scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
Above 50 and 200-day
Close $13.92 is above the 50-day ($9.85) and 200-day ($5.77) averages, and the 50-day is above the 200-day.
See the chart43.5, Distribution
Reading 43.5 is in the Distribution zone.
See the GekkoIndex10.7% above
Price is 10.7% above Gekko Fair Value (more than 5% above).
See fair valueLeans bullish
Last 90 days: 4 open-market insider purchases. Last 30 days: 1 unusual options signal.
See smart moneyReports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings−0.8% on average
From this point in the calendar, the next 20 trading days averaged −0.8% over 5 years, rising in 3 of them.
See seasonalityA description of current data, not a recommendation. How this page works
AbCellera Biologics closed at $13.92 on Sep 28, 2026, +199.4% over the past year, inside a 52-week range of $2.75 to $14.23.
Use the left and right arrow keys to read daily values.
Put ABCL on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
AbCellera Biologics develops a technology platform aimed at finding antibodies that can be turned into new pharmaceutical drugs. The system relies on artificial intelligence to study natural immune responses and pick out antibody candidates with therapeutic potential. This search-and-discovery work for drug-worthy antibodies is the core of what the company is recognized for.
The business operates through discovery programs carried out with outside partners, some finished and others still underway or under contract. As of the end of 2021 it had built up 156 such programs across 36 partner organizations. Among these relationships is a research collaboration and license agreement with Eli Lilly and Company, which stands out as a named partner in its work.
AbCellera was founded in 2012 and is based in Vancouver, Canada. Its shares are listed on the NASDAQ under the ticker ABCL.
AbCellera Biologics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 43.5, in the Distribution zone, down 3.4 points over five sessions.
Down 3.4 points over five sessions, from the Neutral zone.
Reading for Sep 28, 2026
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 42 | −0.4% | +0.3% |
| Accumulation | 237 | +1.6% | +10.7% |
| Neutral | 339 | +1.3% | +1.6% |
| Distribution (current zone) | 44 | +0.2% | +8.1% |
| Selling | 10 | +5.4% | +3.7% |
Average ABCL share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Distribution readings averaged +1.2% over 20 days. Past behaviour doesn’t guarantee future results.
Distribution zone: Institutions potentially offloading. About the five zones →
AbCellera Biologics trades 10.7% above Gekko Fair Value of $12.58, so the shares are overvalued on Gekko’s estimate.
Gekko’s own estimate of what AbCellera Biologics shares are worth, recalculated every trading day.
$12.58
Gekko Fair Value, Sep 29, 2026
10.7% Overvalued
Insiders filed 4 open-market purchases in AbCellera Biologics worth $1.55M, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
$1.55Min 4 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 24 | Hayden Michael R director | Purchase | $570K |
| Aug 18 | John S. Montalbano Director | Purchase | $110K |
| Aug 14 | Michael R Hayden Director | Purchase | $481K |
| Aug 14 | Andrew Booth Chief Financial Officer | Purchase | $384K |
From Form 4 filings, dated to when each was filed.
No trades in ABCL were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
AbCellera Biologics has been buying back its own shares.
From company filings.
1signal, 77% of the flagged premium in calls.
Latest: Bullish flow on Sep 18, $373K in unusual premium.
AbCellera Biologics reports on Nov 5, 2026, after the close (37 days away), and beat the EPS estimate in 5 of its last 8 reports.
Nov 5, 2026
Expected after the close, 37 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 5, 2026 | −$0.18 est −$0.17 | $4.05M est $7.85M | +7.2% |
| May 11, 2026 | −$0.14 est −$0.20 | $8.32M est $5.41M | −5.5% |
| Feb 24, 2026 | −$0.03 est −$0.14 | $44.90M est $6.67M | +5.3% |
| Nov 6, 2025 | −$0.19 est −$0.17 | $8.96M est $6.31M | −16.6% |
| Aug 7, 2025 | −$0.12 est −$0.17 | $17.08M est $6.36M | +3.2% |
| May 8, 2025 | −$0.15 est −$0.17 | $4.24M est $7.31M | +1.0% |
| Feb 27, 2025 | −$0.11 est −$0.15 | $5.05M est $7.58M | −11.3% |
| Nov 4, 2024 | −$0.17 est −$0.14 | $6.51M est $7.58M | −0.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for AbCellera Biologics is $16.67, +19.8% from the last close, from 8 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 8 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 27 | JonesTrading | $25 | +79.6% |
| Sep 24 | Goldman Sachs | $13 | −6.6% |
| Sep 2 | Truist Financial | $30 | +115.5% |
| Aug 17 | BMO Capital | $15 | +7.8% |
| Aug 11 | Truist Financial | $30 | +115.5% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Sep 29, AbCellera Biologics averaged −0.8% across the last 5 years, rising in 3 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.6% | 2 of 5 |
| Next 10 trading days | −0.6% | 2 of 5 |
| Next 15 trading days | +1.8% | 3 of 5 |
| Next 20 trading days | −0.8% | 3 of 5 |
| Next 30 trading days | −4.4% | 2 of 5 |
For scale, ABCL’s typical 20-trading-day move in either direction is about 12.2%.
AbCellera Biologics’s market cap is $4.25B and revenue of $66.17M over the last twelve months.
Coverage of AbCellera Biologics this week reads neutral: 2 positive, 5 neutral and 0 negative headlines.
AbCellera Biologics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 24.4% below |
| GILDGilead Sciences | Neutral | 6.9% above |
| MRNAModerna | Neutral | 73.2% above |
| NTRANatera | Distribution | 25.1% above |
| IQVIQVIA | Neutral | 14.2% above |
| UTHRUnited Therapeutics | Accumulation | 23.6% below |
A peer links to its own page where one exists.
AbCellera Biologics’s market cap is $4.25B at the Sep 28, 2026 close of $13.92, with 324.0M shares outstanding.
The consensus analyst 12-month price target for AbCellera Biologics is $16.67, +19.8% from the last close. Of the 8 firms that rated the stock in the last 90 days, 7 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate AbCellera Biologics is overvalued: the Sep 28, 2026 close of $13.92 is 10.7% above Gekko Fair Value of $12.58. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
AbCellera Biologics is expected to report on Nov 5, 2026, after the market closes (37 days away). Analysts expect earnings of −$0.18 per share on revenue of $6.61M. AbCellera Biologics beat the earnings estimate in 5 of its last 8 reports, moving 6.3% on average across the report.
AbCellera Biologics’s 52-week high is $14.23 and its 52-week low is $2.75; it closed at $13.92 on Sep 28, 2026, +199.4% over the past year. Over the last five years the shares peaked at $20.68 on Sep 28, 2021.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk), 1 as mixed (seasonality) and 2 as headwinds (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.
Gekko flagged 1 unusual options signal in AbCellera Biologics over the last 30 days, with $287K of flagged premium in calls and $86K in puts. The latest, bullish flow, was on Sep 18, 2026 with $373K in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.